Skip to main content

  • Forecasting the impact of the first wave of the COVID-19 pandemic on hospital demand and deaths for the USA and European Economic Area countries

    27 Apr, 2020
    Hospitals need to plan for the surge in demand in each state or region in the United States and the European Economic Area (EEA) due to the COVID-19 pandemic. Planners need forecasts of the most likely trajectory in the coming weeks and will want to plan for the higher values in the range of those forecasts. To date, forecasts of what is most likely to occur in the weeks ahead are not available for states in the USA or for all countries in the EEA.
    This study used data on confirmed COVID-1...
  • Covid-19 and Kidney Transplantation

    27 Apr, 2020

    Kidney-transplant recipients appear to be at particularly high risk for critical Covid-19 illness due to chronic immunosuppression and coexisting conditions.1 At Montefiore Medical Center, we identified 36 consecutive adult kidney-transplant recipients who tested positive for Covid-19 between March 16 and April 1, 2020. A total of 26 recipients (72%) were male, and the median age was 60 years (range, 32 to 77). Fourteen recipients (39%) were black, and 15 recipients (42%) were Hispan...
  • Assessing nitrogen dioxide (NO2) levels as a contributing factor to coronavirus (COVID-19) fatality

    27 Apr, 2020
    AbstractNitrogen dioxide (NO2) is an ambient trace-gas result of both natural and anthropogenic processes. Long-term exposure to NO2 may cause a wide spectrum of severe health problems such as hypertension, diabetes, heart and cardiovascular diseases and even death. The objective of this study is to examine the relationship between long-term exposure to NO2 and coronavirus fatality. The Sentinel-5P is used for mapping the tropospheric NO2 distribution and the NCEP/NCAR reanalys...
  • A real-time dashboard of clinical trials for COVID-19

    27 Apr, 2020
    In response to the global coronavirus disease 2019 (COVID-19) emergency, clinical trial research assessing the efficacy and safety of clinical candidate interventions to treat COVID-19 are emerging at an unprecedented rate. As of April 21, 2020, well over 500 clinical trials have been registered at the various international and national clinical trial registry sites. Findings from randomised clinical trials that have been published as of April 21, 2020, have investigated the effic...
  • How blood group A might be a risk and blood group O be protected from coronavirus (COVID-19) infections (how the virus invades the human via blood group carbohydrate)

    24 Apr, 2020
    AbstractIn the case that O-glycosylation plays a key role in the pathogenesis of coronavirus disease, as was discussed in a previous SARS-CoV infection and is predicted for the current SARS-CoV-2 or COVID-19, this would involve the formation of hybrid, serologically A-like, O-N-acetyl-d-galactosamine (GalNAc)α1-Ser/Thr-R, Tn (“T nouvelle”) structures. Although the angiotensin-converting-enzyme 2 (ACE2) protein, mediating the transferring enzymes, is defined as the primary SARSCoV receptor,...
  • Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications

    24 Apr, 2020
    Background The COVID-19 pandemic caused by SARS-CoV-2 coronavirus threatens global public health. Currently, neutralizing antibodies (NAbs) versus this virus are expected to correlate with recovery and protection of this disease. However, the characteristics of these antibodies have not been well studied in association with the clinical manifestations in patients. Methods Plasma collected from 175 COVID-19 recovered patients with mild symptoms were screened using a safe and sensitive pseudoty...
  • Reinfection could not occur in SARS-CoV-2 infected rhesus macaques

    24 Apr, 2020
    An outbreak of the Corona Virus Disease 2019 (COVID-19), caused by the severe acute respiratory syndrome CoV-2 (SARS-CoV-2), began in Wuhan and spread globally. Recently, it has been reported that discharged patients in China and elsewhere were testing positive after recovering. However, it remains unclear whether the convalescing patients have a risk of “relapse” or “reinfection”. The longitudinal tracking of re-exposure after the disappeared symptoms of the SARS-CoV-2-infected monkeys was p...
  • Endothelial cell infection and endotheliitis in COVID-19

    24 Apr, 2020
    Cardiovascular complications are rapidly emerging as a key threat in coronavirus disease 2019 (COVID-19) in addition to respiratory disease. The mechanisms underlying the disproportionate effect of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on patients with cardiovascular comorbidities, however, remain incompletely understood.
    SARS-CoV-2 infects the host using the angiotensin converting enzyme 2 (ACE2) receptor, which is expressed in several organs, including th...
  • Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2

    23 Apr, 2020
    Abstract BackgroundEffective therapeutics to treat COVID-19 are urgently needed. Remdesivir is a nucleotide prodrug with in vitro and in vivo efficacy against coronaviruses. Here, we tested the efficacy of remdesivir treatment in a rhesus macaque model of SARS-CoV-2 infection.
    MethodsTo evaluate the effect of remdesivir treatment on SARS-CoV-2 disease outcome, we used the recently established rhesus macaque model of SARS-CoV-2 infection that results in transient lower respiratory ...
  • Clinical Characteristics of Pregnant Women with Covid-19 in Wuhan, China

    23 Apr, 2020
    Despite the large and rapidly rising number of cases of coronavirus disease 2019 (Covid-19) and resulting deaths,1 there are limited data about the clinical characteristics of pregnant women with the disease.2,3 We extracted information regarding epidemiologic, clinical, laboratory, and radiologic characteristics, treatment, and outcomes of pregnant women with Covid-19 through the epidemic reporting system of the National Health Commission of China, which stores the medical records o...
  • Researchers identify cells likely targeted by COVID-19 virus

    23 Apr, 2020
    Researchers at MIT; the Ragon Institute of MGH, MIT, and Harvard; and the Broad Institute of MIT and Harvard; along with colleagues from around the world have identified specific types of cells that appear to be targets of the coronavirus that is causing the Covid-19 pandemic.

    Using existing data on the RNA found in different types of cells, the researchers were able to search for cells that express the two proteins that help the SARS-CoV-2 virus enter human cells. They found subsets o...